GeneDx Holdings (WGS) Cash from Operations (2020 - 2026)

GeneDx Holdings (WGS) has reported Cash from Operations for 7 consecutive years, with -$29.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash from Operations fell 378.13% year-over-year to -$29.0 million in Q2 2026; TTM through Jun 2026 was -$48.7 million, a 474.02% decrease from a year earlier, with the FY2025 full-year figure at $33.3 million, up 216.78% from the prior year.
• Cash from Operations was -$29.0 million for Q2 2026 at GeneDx Holdings, up from -$32.4 million in the prior quarter.
• Over five years, Cash from Operations peaked at $15.8 million in Q3 2025 and troughed at -$88.4 million in Q3 2022.
• A 5-year average of -$30.9 million and a median of -$29.4 million in 2023 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations soared 458.75% in 2025 and sank 418.29% in 2026, its largest moves.
• Over 5 years, Cash from Operations stood at -$64.7 million in 2022, then soared by 53.82% to -$29.9 million in 2023, then surged by 89.34% to -$3.2 million in 2024, then grew by 2.92% to -$3.1 million in 2025, then plunged by 837.9% to -$29.0 million in 2026.
• The last three Cash from Operations figures came in at -$29.0 million (Q2 2026), -$32.4 million (Q1 2026), and -$3.1 million (Q4 2025), per Business Quant data.